604,700 Shares in Insmed, Inc. $INSM Acquired by Railway Pension Investments Ltd

Railway Pension Investments Ltd purchased a new position in Insmed, Inc. (NASDAQ:INSM) in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor purchased 604,700 shares of the biopharmaceutical company’s stock, valued at approximately $64,473,000.

Several other institutional investors have also bought and sold shares of INSM. Darwin Global Management Ltd. raised its stake in shares of Insmed by 2.3% in the 4th quarter. Darwin Global Management Ltd. now owns 20,933,277 shares of the biopharmaceutical company’s stock worth $3,644,274,000 after buying an additional 475,832 shares in the last quarter. State Street Corp lifted its holdings in shares of Insmed by 30.6% during the 4th quarter. State Street Corp now owns 5,201,744 shares of the biopharmaceutical company’s stock valued at $905,312,000 after buying an additional 1,217,390 shares during the last quarter. RTW Investments LP raised its holdings in Insmed by 57.0% during the fourth quarter. RTW Investments LP now owns 4,842,879 shares of the biopharmaceutical company’s stock valued at $842,855,000 after buying an additional 1,758,321 shares in the last quarter. Geode Capital Management LLC raised its stake in shares of Insmed by 14.4% in the 4th quarter. Geode Capital Management LLC now owns 4,299,052 shares of the biopharmaceutical company’s stock valued at $751,936,000 after acquiring an additional 539,625 shares in the last quarter. Finally, Orbis Allan Gray Ltd lifted its stake in shares of Insmed by 28.6% in the fourth quarter. Orbis Allan Gray Ltd now owns 4,179,957 shares of the biopharmaceutical company’s stock worth $727,480,000 after buying an additional 929,089 shares during the last quarter.

Insmed Trading Up 2.8%

Shares of INSM stock opened at $121.82 on Tuesday. Insmed, Inc. has a 12-month low of $90.39 and a 12-month high of $212.75. The company has a market capitalization of $26.60 billion, a P/E ratio of -29.64 and a beta of 0.81. The firm has a 50-day moving average price of $114.10 and a 200 day moving average price of $125.70. The company has a quick ratio of 3.40, a current ratio of 3.72 and a debt-to-equity ratio of 0.74.

Insmed (NASDAQ:INSM) last posted its quarterly earnings data on Thursday, August 6th. The biopharmaceutical company reported ($0.06) earnings per share for the quarter, topping the consensus estimate of ($0.67) by $0.61. The company had revenue of $425.49 million during the quarter, compared to analyst estimates of $395.50 million. Insmed had a negative net margin of 76.94% and a negative return on equity of 123.94%. The company’s revenue was up 296.1% on a year-over-year basis. During the same quarter last year, the business posted ($1.70) earnings per share. Research analysts forecast that Insmed, Inc. will post -1.83 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities research analysts have issued reports on INSM shares. Wells Fargo & Company upped their price target on shares of Insmed from $161.00 to $169.00 and gave the company an “overweight” rating in a report on Friday, August 7th. Weiss Ratings restated a “sell (d-)” rating on shares of Insmed in a research note on Friday, July 17th. JPMorgan Chase & Co. lowered their price objective on Insmed from $179.00 to $175.00 and set an “overweight” rating on the stock in a research report on Monday, August 10th. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $235.00 target price on shares of Insmed in a research report on Tuesday, July 28th. Finally, Royal Bank Of Canada decreased their target price on shares of Insmed from $205.00 to $195.00 and set an “outperform” rating on the stock in a research report on Friday, June 5th. Two research analysts have rated the stock with a Strong Buy rating, twenty-two have given a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Buy” and a consensus target price of $205.52.

Insider Activity at Insmed

In other news, COO Roger Adsett sold 239,850 shares of the business’s stock in a transaction on Monday, August 10th. The stock was sold at an average price of $133.27, for a total transaction of $31,964,809.50. Following the completion of the sale, the chief operating officer owned 98,744 shares in the company, valued at $13,159,612.88. The trade was a 70.84% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, CFO Sara Bonstein sold 2,404 shares of Insmed stock in a transaction dated Wednesday, June 3rd. The stock was sold at an average price of $102.27, for a total value of $245,857.08. Following the completion of the sale, the chief financial officer owned 69,082 shares of the company’s stock, valued at approximately $7,065,016.14. The trade was a 3.36% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold 288,291 shares of company stock worth $37,091,566 in the last quarter. Insiders own 2.10% of the company’s stock.

Insmed Profile

Insmed Incorporated is a biopharmaceutical company focused on developing and commercializing therapies for patients with rare and serious diseases, with a particular emphasis on difficult-to-treat pulmonary infections. Headquartered in Bridgewater, New Jersey, the company concentrates its research and development efforts on targeted drug delivery technologies and novel formulations intended to improve clinical outcomes for patients who have limited treatment options.

The company’s principal marketed product is ARIKAYCE (amikacin liposome inhalation suspension), an inhaled liposomal formulation of the antibiotic amikacin that is approved by the U.S.